Search
Oxtriphylline
go.drugbank.com/drugs/DB01303ApprovedOxtriphylline is the choline salt form of theophylline. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Its main physiological reponse i...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesInsulin aspart
go.drugbank.com/drugs/DB01306ApprovedInvestigationalAs a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin aspart, to lower glucose levels in the blood. … Saccharomyces cerevisiae_ (baker's yeast) Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersInsulin detemir
go.drugbank.com/drugs/DB01307ApprovedInvestigational[A2358, A2359, A2360, A44] As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin detemir, to lower glucose levels in the blood. … [A2358, A2359, A2360, A44] Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme InducersKava
go.drugbank.com/drugs/DB01322ApprovedInvestigationalNutraceuticalWithdrawnCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C19 InhibitorsAmobarbital
go.drugbank.com/drugs/DB01351ApprovedIllicitA barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmac...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersHexobarbital
go.drugbank.com/drugs/DB01355ExperimentalA barbiturate that is effective as a hypnotic and sedative.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesRasagiline
go.drugbank.com/drugs/DB01367ApprovedInvestigationalRasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesQuinupristin
go.drugbank.com/drugs/DB01369ApprovedQuinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosom...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsCortisone acetate
go.drugbank.com/drugs/DB01380ApprovedInvestigationalCortisone acetate was first isolate in 1935 and became more widely researched in 1949. Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collag...
Categories: P-glycoprotein inducers, P-glycoprotein substratesGinkgo biloba
go.drugbank.com/drugs/DB01381ApprovedInvestigationalNutraceuticalGinkgo biloba extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of th...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP1A2 Inhibitors